Celano Michael
Chief Financial Officer
Celano Michael has filed 2 SEC Form 4 filings (2 transaction rows) across 1 company, with disclosures dating back to 2026. 2 of those filings fall inside the rolling window. Most recent filing: Nov 12, 2026.
On the most recent filing, Celano Michael is listed as Chief Financial Officer at Larimar Therapeutics, Inc. Inside the rolling window, Celano Michael reported 1 open-market purchase totaling $50K in LRMR and no open-market sales.
Companies traded
Other insiders at LRMR
Insider Buying
$50K
reported purchases (SEC code P)
Insider Selling
$0
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Celano Michael made?
Celano Michael has filed 2 SEC Form 4 filings (2 transaction rows) across 1 company since 2026.
Which companies does Celano Michael trade?
Celano Michael has filed SEC Form 4 disclosures for 1 company, including LRMR.
When was Celano Michael's most recent SEC Form 4 filing?
Celano Michael's most recent SEC Form 4 filing on Tracefour is dated Nov 12, 2026.
What is Celano Michael's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Celano Michael is listed as Chief Financial Officer.
What is Celano Michael's total buy and sell value in the current window?
Inside the rolling retention window, Celano Michael bought $50K and sold $0 based on SEC Form 4 filings.
What was Celano Michael's largest disclosed transaction?
The largest disclosed transaction in the current window is a purchase of 18,460 LRMR shares on 2026-11-11, worth $50K, per SEC Form 4 filings.